Diferencia entre revisiones de «HIV post-exposure prophylaxis»
| Línea 26: | Línea 26: | ||
##Basic regimen + protease inhibitor (e.g. indinavir or nelfinavir) | ##Basic regimen + protease inhibitor (e.g. indinavir or nelfinavir) | ||
== | ==High Risk== | ||
Source | '''Source''' | ||
#Symptomatic HIV/AIDS | #Symptomatic HIV/AIDS | ||
#Acute seroconversion | #Acute seroconversion | ||
#High viral load | #High viral load | ||
Exposure | '''Exposure''' | ||
#Deep injuries | #Deep injuries | ||
#Visible blood on device | #Visible blood on device | ||
Revisión del 04:41 28 mar 2011
Workup
- Td
- Hepatitis B PEP for non-vaccinated
- Hepatitis B immunoglobulin and/or vaccine
- Source labs
- Rapid HIV, hep pannel, RPR?
- Exposed labs
- Rapid HIV, hep pannel, RPR?
- Consider HIV PEP
- CBC, C7, LFTs, Icon if considering HIV PEP
^Currently no PEP for Hep C
HIV PEP
- ~79% transmission reduction
- Initiate ASAP (goal = 1-2 hours)
- >36 hours: normally deferred, unless particularly high risk
- Common side-effects = constitutional, gastrointestinal
Specific Regimens (CDC)
- Basic
- Exposures for which there is a recognized transmission risk
- 4 week, 2 drug regimen (normally zidovudine and lamivudine)
- Expanded
- High risk exposures
- Basic regimen + protease inhibitor (e.g. indinavir or nelfinavir)
High Risk
Source
- Symptomatic HIV/AIDS
- Acute seroconversion
- High viral load
Exposure
- Deep injuries
- Visible blood on device
- Injuries sustained placing a catheter in a vein/artery
Source
8/07 DONALDSON
